Ophthalmology

Top Story

PUBLICATION EXCLUSIVE: Improvements in instruments, sterilization and anesthesia set stage for office-based vitreoretinal surgeries

May 27, 2017

Remarkable advances in vitreoretinal surgery have occurred in the past 20 years. Diversified and miniaturized instruments have been produced, surgical time has dropped, and most procedures are done under local anesthesia, all of which have made hospitalization unnecessary in many cases. The number of vitreoretinal procedures performed in an outpatient setting has grown, and some surgeons feel that the time is about right to shift surgery to the office.

“There are currently 5,500 ambulatory surgical centers in the U.S. doing 25 million surgeries. We feel comfortable with it, at least in uncomplicated, routine cases,” Dante J. Pieramici, MD, said.

Blog

BLOG: Whither AzaSite, part whatever — I give up

May 26, 2017
Has there ever a better medicine that had a rougher go than AzaSite? Seriously. AzaSite is the floppy eyelid syndrome of ophthalmic medications. Here we have a highly…
Meeting NewsVideo

VIDEO: Neurostimulator the latest tool for dry eye treatment

May 26, 2017
LOS ANGELES ― At the American Society of Cataract and Refractive Surgery meeting here, Cynthia A. Matossian, MD, discusses the TrueTear neurostimulator device from…
Blog

BLOG: The three Cs of practice consolidation

May 26, 2017
While the future of the Affordable Care Act remains uncertain, one element of health care “reform” won’t go away: Costs must be contained. Inevitably…
Cover Story

Private equity offers new option for ophthalmology practice consolidation

Ocular Surgery News U.S. Edition, June 10, 2017
Ophthalmologists and ophthalmology practices are steering toward consolidation in a fragmented market, and private equity firms may offer a new option for physicians as…
More News Headlines »
Clinical Science

Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema

Ophthalmic Surgery, Lasers and Imaging Retina, May 2017, Volume 48 Issue 5
To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron…
More »
CME

Non-infectious Uveitis: Moving Beyond the Standard of Care with an Eye on the Evidence

This activity is supported by educational grants from AbbVie, Inc.

Uveitis is one of the leading causes of preventable blindness worldwide with a prevalence in the US of about 38 cases…
More »
Featured
Video
Meeting News

VIDEO: DREAM study demonstrates Prokera Slim eases dry eye disease in severe cases

May 20, 2017
More »
Advertisement
Advertisement